Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648553 | 0.90 | ESR2 (0.45) | ESR2NR1H2HPGDSMKNK1SMN1; SMN2 | |
| SCHEMBL3693556 | 0.85 | ESR2 (0.44) | ESR2NR1H2MKNK1ADORA1GRM5 | |
| SCHEMBL951930 | 0.84 | ESR2 (0.44) | ESR2NR1H2ADORA1GRM5GRM1 | |
| SCHEMBL952114 | 0.83 | ESR2 (0.45) | ESR2NR1H2MKNK1ADORA1GRM5 | |
| SCHEMBL13852292 | 0.82 | TP53 (0.41) | ESR2NR1H2HPGDSMKNK1SMN1; SMN2 | |
| SCHEMBL4219188 | 0.82 | MKNK1 (0.45) | ESR2NR1H2HPGDSMKNK1SMN1; SMN2 | |
| SCHEMBL18971984 | 0.81 | ADORA1 (0.44) | ESR2NR1H2HPGDSMKNK1ADORA1 | |
| SCHEMBL3696289 | 0.77 | NR1H2 (0.43) | ESR2NR1H2MKNK1GRM5GRM1 | |
| SCHEMBL951850 | 0.77 | ESR2 (0.48) | ESR2NR1H2ADORA1GRM5GRM1 | |
| SCHEMBL16434777 | 0.76 | GRM1 (0.56) | GRM5GRM1CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188266-B1 | Novel piperazine amide derivatives | HOFFMANN LA ROCHE (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-8288541-B2 | Piperazine amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2188266-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009021868-A2 | NOVEL PIPERAZINE AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048264-A1 | PIPERAZINE AMIDE DERIVATIVES | NR1H2, NR1H3, NR1I2 | ESR2 36/4885NR1H2 1/4885HPGDS 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.